… Biosimilars of infliximab and adalimumab are also available for the treatment of IBD. This
review summarizes the clinical pharmacology, … Citation27 Some of the common side effects …

… De-escalating therapy, the role of therapeutic drug monitoring and the use of biosimilars, …
to multifactorial mechanisms including disease characteristics, as well as drug and treatment …

… drug elimination mediated through TMDD will mainly depend on the drug dose, target capacity
(density), drug … Other molecular aspects of pharmacology, which add an additional layer …

… Drug Administration (FDA) and the European Medicines Agency (EMA), the clinical efficacy
and side effects of a biosimilar … of therapeutic drug monitoring for both RPs and biosimilars …

… of biosimilars of the anti-TNF agents allow drug costs to be … infliximab dosing based on clinical
features (the maintenance phase… in more efficient use of the drug – in particular, increased …

… , has significantly improved inflammatory bowel disease (IBD… Use of biosimilars in inflammatory
bowel disease: statements … scientific aspects related to biosimilars in inflammatory bowel …

… The first approved biosimilar drug was a biosimilar recombinant human growth hormone, …
inhibition of the TNF-α signalling pathway, they share some common features including similar …

… of biosimilar IFX in patients with CD and UC naïve to anti-TNF … The mean disease duration
at antiTNF therapy start was 6.2 (±… : Pharmacological aspects of anti-TNF biosimilars in in- …

… Corresponding price reductions may force pharmaceutical companies to lower prices of …
Our model included various aspects of the market entry of a biosimilar, including price …

… 2016 the US Food and Drug Administration (FDA) registered biosimilar infliximab for all …
countries employ demand-side incentives to encourage the uptake of biosimilars. In the US, …